Expression and characterization of purinergic receptors in rat middle meningeal artery-potential role in migraine

PLoS One. 2014 Sep 29;9(9):e108782. doi: 10.1371/journal.pone.0108782. eCollection 2014.

Abstract

The dura mater and its vasculature have for decades been central in the hypothesis of migraine and headache pathophysiology. Although recent studies have questioned the role of the vasculature as the primary cause, dural vessel physiology is still relevant in understanding the complex pathophysiology of migraine. The aim of the present study was to isolate the middle meningeal artery (MMA) from rodents and characterize their purinergic receptors using a sensitive wire myograph method and RT-PCR. The data presented herein suggest that blood flow through the MMA is, at least in part, regulated by purinergic receptors. P2X1 and P2Y6 receptors are the strongest contractile receptors and, surprisingly, ADPβS caused contraction most likely via P2Y1 or P2Y13 receptors, which is not observed in other arteries. Adenosine addition, however, caused relaxation of the MMA. The adenosine relaxation could be inhibited by SCH58261 (A2A receptor antagonist) and caffeine (adenosine receptor antagonist). This gives one putative molecular mechanism for the effect of caffeine, often used as an adjuvant remedy of cranial pain. Semi-quantitative RT-PCR expression data for the receptors correlate well with the functional findings. Together these observations could be used as targets for future understanding of the in vivo role of purinergic receptors in the MMA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / pharmacology
  • Animals
  • Caffeine / pharmacology
  • Intracellular Space / metabolism
  • Male
  • Meningeal Arteries / drug effects
  • Meningeal Arteries / metabolism*
  • Meningeal Arteries / physiopathology
  • Migraine Disorders / metabolism*
  • Migraine Disorders / physiopathology
  • Purine Nucleotides / pharmacology
  • Pyrimidine Nucleotides / pharmacology
  • Rats, Sprague-Dawley
  • Receptors, Purinergic / genetics
  • Receptors, Purinergic / metabolism*
  • Vasoconstriction / drug effects
  • Vasoconstrictor Agents / pharmacology
  • Vasodilator Agents / pharmacology

Substances

  • Purine Nucleotides
  • Pyrimidine Nucleotides
  • Receptors, Purinergic
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Caffeine
  • Adenosine

Grants and funding

This work was supported by the Lundbeck Foundation, Lundbeck Grant of Excellence. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.